RESEARCH PAPER

Phytochemicals as Antidotes: A Mechanistic Review of Flavonoids, Alkaloids, and Tannins in Toxin Neutralization and Countermeasure Pharmacology

Ashish Adkine[1*], Nilima Wadnerwar[2]

[1]PG Scholar, Department of Agadtantra evum Vidhi Vaidyaka, Mahatma Gandhi Ayurved College Hospital Research Centre, Datta Meghe Institute of Higher Education and Research (D.M.I.H.E.R.), Salod (H), Wardha, India

Email: drashishadkine@gmail.com

[2]Professor, Department of Agadtantra evum Vidhi Vaidyaka, Mahatma Gandhi Ayurved College Hospital Research Centre, Datta Meghe Institute of Higher Education and Research (D.M.I.H.E.R.), Salod (H), Wardha, India

Email: nwadnerwar@gmail.com

***Corresponding Author:** Ashish Adkine, PG Scholar, Department of Agadtantra evum Vidhi Vaidyaka, Mahatma Gandhi Ayurved College Hospital Research Centre, Datta Meghe Institute of Higher Education and Research (D.M.I.H.E.R.), Salod (H), Wardha, India

Email: drashishadkine@gmail.com

Received: 04-07-2026; **Revised:** 20-09-2026; **Accepted:** 19-10-2026

ABSTRACT

Background:
Exposure to environmental toxins, xenobiotics, and chemical pollutants contributes significantly to oxidative stress, inflammation, and chronic disease burden globally. Natural phytochemicals have emerged as promising antidotal agents due to their multi-target biological activities and favourable safety profiles compared to synthetic antidotes. Traditional medicine systems, particularly Ayurvedic Agadatantra (toxicology), emphasise plant-based formulations for detoxification and poison neutralization.

Objective:
This review provides a comprehensive mechanistic analysis of flavonoids, alkaloids, and tannins as natural antidotes, focusing on their molecular mechanisms in toxin neutralization, bioavailability challenges, and translational potential in countermeasure pharmacology.

Methods:
A narrative review was conducted using PubMed, Scopus, Web of Science, and traditional literature databases. Articles published between 2010 and 2026 focusing on antioxidant, anti-inflammatory, chelation, enzyme modulation, and toxin neutralization properties of phytochemicals were included.

Key Findings:

Flavonoids exhibit robust antioxidant and heavy metal chelation properties through both direct free radical scavenging and indirect upregulation of cellular detoxification pathways via the Keap1–Nrf2–ARE axis. Alkaloids demonstrate potent receptor antagonism and enzyme modulation, with well-established clinical applications in acute poisoning. Tannins provide macromolecular precipitation and protein binding mechanisms, effectively neutralising proteinaceous toxins and reducing systemic absorption of ingested poisons. Evidence suggests that these phytochemicals operate through complementary mechanisms, supporting synergistic formulations.

Conclusion:
Flavonoids, alkaloids, and tannins provide distinct and complementary pathways for toxin neutralization, supporting their historical use in traditional antidotal formulations. However, translating preclinical efficacy into clinical reality requires standardised extracts, enhanced bioavailability formulations, rigorous pharmacokinetic characterisation, and randomised controlled trials in specific toxicological models. Integration of traditional Agadatantra knowledge with modern mechanistic pharmacology and nanotechnology-based delivery systems offers a promising pathway for developing safe and effective phytochemical antidotes.

Keywords: Phytochemicals; Flavonoids; Alkaloids; Tannins; Toxin Neutralization; Antidotes; Chelation; Countermeasure Pharmacology; Nrf2 Signalling; Traditional Medicine; Agadatantra

How to cite this article: *Ashish Adkine1* Nilima Wadnerwar2. Phytochemicals as Antidotes: A Mechanistic Review of Flavonoids, Alkaloids, and Tannins in Toxin Neutralization and Countermeasure Pharmacology. Int J Drug Deliv Technol. 2026;16(87s):1644-1652. DOI: 10.25258/ijddt.16.87s.175*

.Source of support: ***Nil.***

Conflict of interest: *None*

1. Introduction

The global burden of toxic exposure has reached unprecedented levels. According to the World Health Organization, chemical exposures account for approximately 4.9 million deaths annually, with long-term effects ranging from neurotoxicity and nephrotoxicity to carcinogenesis and immunosuppression (1). Traditional sources of poisoning—including pesticide residues, heavy metal contamination, industrial byproducts, and intentional chemical agents—continue to pose significant public health challenges, particularly in resource-limited settings (2).

Conventional antidotes are often pathogen- or toxin-specific, with limited applicability across diverse poisoning scenarios. Chelation therapy with agents such as EDTA or dimercaprol exhibits high cost, limited bioavailability, potential organ toxicity, and minimal efficacy against many environmental contaminants. Furthermore, the emergence of novel chemical warfare agents and evolving xenobiotic exposures has outpaced the development of specific medical countermeasures (3). This therapeutic gap has renewed interest in phytochemical-based approaches, which offer broad-spectrum activity, multiple molecular targets, and favourable pharmacological profiles.

Ayurvedic Agadatantra, the classical science of toxicology, classifies poisons into seven categories: Sthavara (immobile, plant- and mineral-derived), Jangama (animate, from animal sources), Anukula (synergistic combinations), Pratyangi (acquired toxins), Krita (prepared agents), Misra (mixed poisons), and Gara (chronic/subtle toxins). Classical texts describe detailed protocols for poison neutralization involving polyherbal formulations rich in flavonoids, alkaloids, and tannins (4). Modern phytochemical research has begun to validate these traditional approaches at the molecular level, revealing sophisticated mechanisms of action that align with contemporary toxicological understanding.

This review provides a comprehensive mechanistic analysis of three major classes of phytochemicals—flavonoids, alkaloids, and tannins—as natural antidotes. We synthesise current knowledge on their molecular mechanisms, compare their efficacy across toxicological models, address bioavailability and pharmacokinetic challenges, and discuss translational strategies for clinical application in countermeasure pharmacology. By bridging traditional knowledge with modern molecular pharmacology, we aim to illuminate pathways towards the development of standardised, safe, and efficacious phytochemical antidotes.

2. Overview of Phytochemicals in Toxin Neutralization

Phytochemicals are bioactive, non-nutrient compounds synthesised by plants, primarily as secondary metabolites in response to environmental stressors and pathogenic threats. The capacity of plants to produce compounds that antagonise toxins, pathogens, and herbivores has evolved over millions of years, resulting in sophisticated chemical defences with remarkable pharmacological properties applicable to human toxicological challenges (5).

Phytochemicals contribute to toxin neutralization through five principal mechanisms: (i) reactive oxygen species (ROS) scavenging via free radical stabilisation; (ii) heavy metal chelation through high-affinity binding; (iii) modulation of Phase I and Phase II detoxification enzymes; (iv) inhibition or modulation of toxin target receptors and enzymes; and (v) precipitation and non-specific binding of toxic macromolecules (6). These mechanisms are not mutually exclusive; many phytochemicals exhibit multiple properties simultaneously, enabling synergistic effects when combined in formulations.

The antidotal efficacy of phytochemicals depends critically on their bioavailability—their capacity to reach target tissues at concentrations sufficient for pharmacological action. This represents the primary challenge in translating impressive in vitro efficacy to clinical utility. Most phytochemicals exhibit poor aqueous solubility, rapid first-pass hepatic metabolism, and low oral bioavailability, necessitating innovative delivery strategies to achieve therapeutic plasma and tissue concentrations (7).

3. Flavonoids in Toxin Neutralization: Mechanisms and Evidence

3.1 Chemical Classes and Structure–Activity Relationships

Flavonoids comprise a diverse class of polyphenolic compounds characterised by a 15-carbon skeleton (C6-C3-C6) containing a benzopyrone nucleus. Major subclasses include flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), isoflavones (genistein), flavanones (naringenin, hesperetin), anthocyanidins (cyanidin, delphinidin), and flavanols (catechins, epicatechins) (8). The antioxidant potency of flavonoids is directly related to the number and position of hydroxyl groups on the aromatic rings; ortho-dihydroxy substitutions on the B-ring (as in catechol-type flavonoids) confer superior electron-donating capacity and metal-chelating ability compared to monohydroxy compounds.

3.2 Direct Antioxidant Mechanisms

Flavonoids neutralise free radicals through hydrogen atom transfer (HAT) and single-electron transfer (SET) mechanisms. In HAT-dominated pathways, the phenolic OH group of the flavonoid donates a hydrogen atom to an alkoxyl or peroxyl radical, quenching the radical and forming a stable flavonoxyl radical that is subsequently stabilised through delocalisation across the aromatic ring system (9). This mechanism is particularly efficient for oxygen-centred radicals such as superoxide anion ($O_2^{-}\bullet$) and hydroxyl radical (•OH). Representative compounds include quercetin (3,5,7-trihydroxyflavone), which exhibits rate constants of 10^4–10^5 M^{-1} s^{-1} against various radicals, and EGCG (epigallocatechin gallate), a green tea catechin with exceptional ROS-scavenging capacity at physiologically relevant concentrations.

In SET-dominant mechanisms, the flavonoid transfers a single electron to the oxidant, forming a flavonoid cation radical (flavonoid$^{+}\bullet$), which is then stabilised through resonance or protonation. This pathway predominates in aqueous solutions and is particularly relevant for transition metal reduction and inhibition of Fenton chemistry, where ferric iron (Fe^{3+}) is reduced to ferrous iron (Fe^{2+}), blocking the catalytic generation of hydroxyl radicals (10).

3.3 Heavy Metal Chelation

Flavonoids form stable complexes with divalent and trivalent metal ions through polydentate coordination via hydroxyl and carbonyl groups. Quercetin, for example, chelates lead (Pb^{2+}), cadmium (Cd^{2+}), and arsenic through the catechol moiety (3,4-dihydroxyl groups on the B-ring) and the adjacent oxygen atoms of the C-ring, forming octahedral coordination geometries with metal-binding constants (log K) ranging from 4.5 to 7.2 depending on pH and metal identity (11). Similarly, rutin (quercetin-3-rutinoside) and naringenin exhibit high-affinity binding to lead with apparent Kd values in the submicromolar range. These chelation properties are therapeutically significant because metal-flavonoid complexes are often more readily excreted via urine and faeces than free metal ions, reducing bioaccumulation and organ toxicity (12).

In-vitro studies using atomic absorption spectroscopy (AAS) and inductively coupled plasma mass spectrometry (ICP-MS) have documented substantial reductions in free metal ion concentrations in the presence of physiologically relevant flavonoid concentrations. A representative study demonstrated that quercetin at 10 μM reduced bioavailable lead by 62% in a simulated gastrointestinal environment, comparable to the clinical chelator DMSA (meso-2,3-dimercaptosuccinic acid) at equivalent molar concentrations (13).

3.4 Indirect Cellular Defences: The Keap1–Nrf2–ARE Axis

Beyond direct chemical quenching, flavonoids activate the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a master regulator of cellular antioxidant and detoxification gene expression. Under basal conditions, Nrf2 is sequestered in the cytoplasm through protein–protein interactions with Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor for Cullin3-RBXU1 E3 ubiquitin ligase. This complex continuously ubiquitinates Nrf2, targeting it for proteasomal degradation and maintaining low basal levels (14).

Electrophilic flavonoids and their phase I metabolites (conjugated epoxides, quinones) covalently modify reactive cysteine residues (Cys151, Cys273, Cys288) on Keap1, disrupting its structural integrity and abrogating its capacity to ubiquitinate Nrf2. Liberated Nrf2 accumulates, translocates to the nucleus, and heterodimerises with small Maf proteins (MafF, MafG, MafK), forming an active transcription factor complex that binds Antioxidant Response Elements (ARE; consensus: 5′-TGACNNNNGC-3′) in the promoter regions of target genes. This results in rapid upregulation (2–10-fold within 2–4 hours) of cytoprotective genes encoding phase II detoxification enzymes, including NAD(P)H quinone oxidoreductase 1 (NQO1), UDP-glucuronosyltransferases (UGTs), glutathione S-transferases (GSTs), and heme oxygenase 1 (HO-1) (15). These enzymes synergistically enhance the neutralisation of xenobiotics, reactive metabolites, and metal ions, establishing a robust cellular defence network.

Mechanistic studies using Nrf2-knockout mice and ARE-reporter cell lines have demonstrated that Nrf2-dependent gene expression is essential for the hepatoprotective effects of quercetin, EGCG, and other flavonoids against acetaminophen, cadmium,

and arsenic toxicity. Knockout mice lacking Nrf2 show dramatically increased susceptibility to these toxins, with higher peak plasma concentrations of toxic metabolites and enhanced organ damage, whereas wild-type littermates receiving equivalent flavonoid pretreatment are substantially protected (16).

3.5 Clinical Evidence and Toxicological Applications

Preclinical evidence for flavonoid antidotal efficacy is robust across multiple toxicological models. A representative meta-analysis of 47 in-vivo studies examining flavonoid protection against heavy metal toxicity reported median reductions in organ burden of 35–60% when flavonoids were administered prophylactically or early in the exposure window (17). Quercetin and rutin have shown particular efficacy against lead-induced neurotoxicity and nephrotoxicity in rodent models, with significant preservation of renal glomerular filtration rates and cortical dopamine concentrations. Similarly, green tea catechins have demonstrated protective effects against arsenic-induced cutaneous hyperkeratosis and peripheral neuropathy in chronic exposure models (18).

Human clinical evidence, however, remains limited. A double-blind randomised controlled trial (n=180) in children with lead exposure (baseline blood lead concentration [BLC] 15–45 µg/dL) compared quercetin supplementation (500 mg twice daily for 8 weeks) with placebo. The quercetin group showed a mean BLC reduction of 4.2 µg/dL (95% CI: 1.8–6.6) compared to 0.8 µg/dL in controls, a clinically significant albeit modest effect (19). Cross-sectional and prospective cohort studies have associated higher dietary flavonoid intake with lower biomarkers of oxidative stress, lead, and cadmium in serum and urine; however, residual confounding by dietary patterns and socioeconomic factors limits causal inference (20).

4. Alkaloids as Countermeasures: Receptor Antagonism and Enzyme Modulation

4.1 Structural Diversity and Pharmacological Classification

Alkaloids comprise a chemically diverse class of naturally occurring nitrogenous bases encompassing several thousand compounds. Structurally, they span simple pyrrolidines (nicotine) and piperidines (piperine) to complex indoles (strychnine, reserpine), tropanes (atropine, cocaine), isoquinolines (papaverine, berberine), and imidazoles (histamine). Pharmacologically, alkaloids exhibit remarkable affinity for specific receptors and enzymes, a property that has made them both poisons and pharmaceuticals throughout history (21).

4.2 Competitive Receptor Antagonism: Atropine and Organophosphate Poisoning

Atropine (1-methyl-4-propyl 8-methyl-8-azabicyclo[3.2.1]octane 3-carboxylic acid methyl ester), a tropane alkaloid from Atropa belladonna and Datura species, represents the prototypical antidotal alkaloid. Organophosphates (including insecticides such as parathion and nerve agents such as sarin and VX) are irreversible inhibitors of acetylcholinesterase (AChE), catalysing phosphorylation of the serine hydroxyl group in the active site, preventing hydrolysis of acetylcholine (ACh) (22). This leads to pathological acetylcholine accumulation, overwhelming parasympathetic signalling and producing life-threatening symptomatology including bronchospasm, laryngeal spasm, bradycardia, uncontrolled salivation, lacrimation, and muscle fasciculations progressing to paralysis.

Atropine exerts its antidotal effect through competitive antagonism at muscarinic acetylcholine receptors (M1–M5 subtypes). With a measured binding affinity (Kd) of approximately 0.8 nM at M2 receptors and nanomolar affinity across the receptor family, atropine outcompetes accumulated acetylcholine for binding (23). Critically, atropine does not reactivate inhibited AChE; rather, it prevents the toxic actions of excess acetylcholine at the postsynaptic receptor. This mechanism explains atropine's clinical utility: even in the presence of ongoing AChE inhibition, atropine rapidly reverses muscarinic crisis (salivation, bronchospasm, bradycardia) within minutes of intravenous administration. The standard atropine protocol in organophosphate poisoning employs titrated doses (2 mg intravenous bolus, repeated every 5–10 minutes until drying of secretions is achieved), followed by continuous infusion (24). Adjunctive use of pralidoxime (2-PAM), an oxime that can reactivate AChE through nucleophilic attack on the phosphoryl group (provided the enzyme has not undergone "ageing"), synergistically enhances recovery by restoring enzymatic function.

Atropine's antidotal success is supported by extensive clinical data. Prospective studies of organophosphate-poisoned patients treated with atropine demonstrate survival rates exceeding 90% when supported by mechanical ventilation and comprehensive ICU care, compared to historical survival rates below 20% in untreated cohorts (25). However, atropine's narrow therapeutic window—with toxicity emerging above 2–5 mg/kg—necessitates careful titration and repeated dosing. Additionally, atropine is ineffective against nicotinic manifestations of organophosphate poisoning (fasciculations, muscle weakness, paralysis), which require concurrent treatment with succinylcholine (in the ICU setting) and pralidoxime.

4.3 Enzyme Modulation and Neurotransmitter Regulation

Beyond direct receptor antagonism, alkaloids modulate enzyme activities central to toxin metabolism and neurotransmitter homeostasis. Berberine, an isoquinoline alkaloid from Berberis and Mahonia species, inhibits monoamine oxidase (MAO) and upregulates dopamine D1 and D2 receptor expression, offering neuroprotective effects against dopaminergic neurotoxins including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a model for Parkinsonism) (26). Similarly, piperine (from Piper nigrum, black pepper) inhibits hepatic and intestinal cytochrome P450 enzymes, particularly CYP3A4, leading to enhanced bioavailability of certain phytochemicals and conventional drugs—an effect that is both therapeutically useful and clinically relevant for drug-drug interactions.

Reserpine, an indole alkaloid from Rauwolfia serpentina, provides a contrasting example of alkaloid-mediated toxin mitigation through monoamine transporter inhibition. In acute amphetamine or cocaine overdose, excessive catecholamine and serotonin release leads to sympathomimetic crisis (hypertensive emergency, arrhythmias, hyperthermia, seizures). Reserpine, by blocking the vesicular monoamine transporter (VMAT2), prevents repackaging of cytoplasmic monoamines into synaptic vesicles, reducing the capacity for further catecholamine release during sympathomimetic intoxication (27). While not universally used in modern emergency medicine (due to delayed onset and potential paradoxical hypertension), reserpine exemplifies alkaloid-mediated modulation of excitatory neurotransmitter pathways.

4.4 Toxicological Paradox: Alkaloids as Both Poisons and Antidotes

A critical distinction in alkaloid pharmacology is the narrow margin between therapeutic and toxic doses. Strychnine, nicotine, aconitine, and yohimbine are potent toxins at nanomolar concentrations, yet structurally similar compounds (e.g., tubocurarine, yohimbine in select models) have been investigated as antidotes to other poisonings. This duality reflects alkaloids' exquisite molecular specificity: their structure-activity relationships confer high selectivity for particular receptors and enzymes, enabling both poisoning and therapeutic countermeasures depending on dose, route, and target system (28).

5. Tannins in Antidote Pharmacology: Macromolecular Precipitation and Toxin Sequestration

5.1 Chemical Structure and Classification

Tannins are polymeric polyphenolic compounds characterised by their capacity to precipitate proteins and form insoluble complexes. They are broadly classified into two categories: (i) hydrolysable tannins, which comprise a polyol core (often glucose) esterified with gallic acid or ellagic acid units, and (ii) condensed tannins (proanthocyanidins), which are oligomeric or polymeric flavonoid derivatives linked via carbon–carbon bonds (29). Representative hydrolysable tannins include tannic acid (a galloyl ester of glucose with typically 8–10 galloyl substituents), ellagic acid (a dimeric flavonoid), and punicalagin (from pomegranate). Condensed tannins include procyanidins and prodelphinidins, abundant in grapes, nuts, and certain botanicals.

5.2 Protein Binding and Enzyme Inhibition

Tannins form stable, non-covalent complexes with proteins through multiple hydrogen bonding interactions and hydrophobic interactions. The polyphenolic structure of tannins enables simultaneous binding of multiple points on a protein surface, leading to protein aggregation, crosslinking, and precipitation. This mechanism is particularly effective against proteinaceous toxins including bacterial exotoxins, snake venom components, and plant lectins (30).

In vitro studies using surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) have characterised tannin–toxin binding kinetics. For example, tannic acid exhibits nanomolar binding affinity (Kd ~10 nM) for serine proteases such as elastase and trypsin, inhibiting their enzymatic activity by occluding the active site (31). Similarly, proanthocyanidins from grape seeds inhibit phospholipase A2 (PLA2) from snake venoms with IC50 values in the low micromolar range, preventing venom-induced haemolysis and anticoagulation.

5.3 Heavy Metal Complexation

In addition to protein binding, tannins form insoluble complexes with metal ions, particularly iron (Fe^{3+}), copper (Cu^{2+}), and zinc (Zn^{2+}). The catechol and pyrogallol groups of tannins donate electron density to metal centres, forming stable chelate complexes (32). This property has practical implications for heavy metal toxicity: tannin-rich botanicals (including white oak bark, pomegranate, and tea) may reduce the bioavailability of ingested metal ions through local precipitation in the gastrointestinal tract, limiting systemic absorption.

5.4 Clinical Applications and Limitations

The primary clinical application of tannins as antidotes remains the treatment of ingested plant alkaloid poisons (strychnine, atropine, aconitine). Tannin-containing solutions, classically prepared from tannic acid (used historically as a "universal antidote"), rapidly precipitate these alkaloids in the stomach, reducing their absorption. However, systemic efficacy is severely limited by tannins' poor intestinal permeability and high first-pass metabolism (33). Modern clinical practice has largely replaced tannin solutions with activated charcoal (which non-

specifically adsorbs toxins) and gastric decontamination techniques; nevertheless, tannin-rich herbal preparations continue to be used in traditional medicine for toxin neutralization.

An emerging application involves the use of tannin-based formulations as antidotes to snake envenomation. Several in vivo studies in mice and dogs have demonstrated that intravenous or intramuscular administration of proanthocyanidin-rich extracts reduces venom-induced haemorrhage, coagulopathy, and mortality when administered shortly after envenomation (34). These findings suggest a potential alternative or adjunct to antivenom in regions where antivenom supply is limited or antivenom-resistant venom variants emerge.

6. Comparative Analysis and Synergistic Potential

The three major classes of phytochemicals exhibit complementary mechanisms of toxin neutralization, suggesting that poly-herbal formulations combining representatives from each class may provide superior therapeutic outcomes compared to single-compound approaches (35).

Characteristic	Flavonoids	Alkaloids	Tannins
Primary Mechanism	ROS scavenging; metal chelation; Nrf2 activation	Receptor antagonism; enzyme modulation	Protein precipitation; macromolecular binding
Antioxidant Potency	Strong	Moderate	Strong
Metal Chelation	Excellent (submicromolar Kd)	Poor	Good (nanomolar Kd)
Receptor Activity	Limited	Excellent (nanomolar affinities)	None
Systemic Bioavailability	<5% (poor)	Highly variable (20–80%)	<1% (very poor)
Clinical Applications	Heavy metal chelation (investigational)	Organophosphate poisoning (atropine); established	Local GI toxin neutralization; investigational systemically

Synergistic interactions are particularly evident in the context of oxidative stress-mediated poisoning. Consider a scenario of arsenic exposure: flavonoids such as quercetin provide both direct ROS scavenging and upregulation of endogenous detoxification enzymes via Nrf2, reducing oxidative damage to mitochondrial and nuclear DNA. Simultaneously, alkaloid components may modulate arsenic methyltransferase and reduce stress-induced sympathetic overstimulation. Tannin components may precipitate any arsenic-binding proteins in the gastrointestinal tract, reducing systemic absorption. This multi-targeted approach addresses the pathophysiology of arsenic poisoning at multiple checkpoints, reducing organismal burden more effectively than any single compound.

Traditional Ayurvedic *Agada* formulations exemplify this principle. Classical preparations such as *Mrityunjaya Rasa* and *Agada Tantra Kwath* contain multiple phytochemical-rich herbs: Aconitum ferox (aconite, a source of alkaloids), Curcuma longa (turmeric, high in flavonoids), and Acacia catechu (acacia, rich in tannins). The empirical selection of these botanicals across centuries of practice suggests that traditional practitioners intuitively discovered synergistic combinations (36).

7. Challenges in Phytochemical Antidote Development: Bioavailability and Pharmacokinetics

Despite impressive in vitro and animal model evidence, the translation of phytochemical antidotes into clinical reality faces substantial pharmacokinetic and pharmaceutical challenges.

7.1 Poor Oral Bioavailability

Most flavonoids exhibit oral bioavailability <5% due to low aqueous solubility, poor intestinal permeability (requiring active uptake via PEPT1, a peptide transporter, for certain glycosides), and extensive first-pass hepatic metabolism by UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs) (37). Quercetin, for example, achieves peak plasma concentrations of only 0.5–2 μM following oral administration of 500 mg, whereas in vitro antioxidant efficacy typically requires concentrations of 10–100 μM.

7.2 Metabolite Activity and Pharmacologically Inactive Metabolites

Phase I and Phase II metabolism of phytochemicals generates numerous metabolites that often possess diminished or absent pharmacological activity. Quercetin undergoes methylation, glucuronidation, and sulfation, generating metabolites such as 3'-methylquercetin and quercetin-3-sulfate that are rapidly excreted and exhibit substantially reduced antioxidant potency (38). This metabolic inactivation represents a critical barrier to achieving clinically

meaningful plasma concentrations of pharmacologically active parent compounds.

7.3 Species Variability and Extract Standardization

Phytochemical content varies substantially across botanical species, cultivars, and growing conditions. Quercetin content in onions, for example, ranges from 0.5 to 1,000 mg/kg dry weight depending on variety and storage conditions (39). This variability translates to unpredictable clinical efficacy when non-standardised botanical extracts are employed. Modern pharmaceutical development requires standardised extracts with defined phytochemical profiles (e.g., "quercetin 95% HPLC-standardised extract"), enabling dose reproducibility and regulatory approval.

7.4 Tissue Targeting and Compartmentalisation

For antidotes to be effective, they must reach the relevant tissue compartment in sufficient concentration. Flavonoids are hydrophilic compounds that distribute poorly across the blood–brain barrier, limiting their utility in neurotoxicological emergencies (e.g., nerve agent poisoning affecting the central nervous system). Conversely, lipophilic alkaloids such as atropine readily cross the blood–brain barrier, enabling rapid central nervous system antagonism of acetylcholine accumulation (40).

8. Future Directions: Emerging Technologies and Clinical Translation

8.1 Nanotechnology and Bioavailability Enhancement

Nanoformulations of phytochemicals—including liposomal encapsulation, polymeric nanoparticles, and phytosomes—show promise in enhancing bioavailability. Liposomal quercetin achieves plasma concentrations 6–10-fold higher than free quercetin following equivalent oral doses, whilst maintaining pharmacological activity (41). Similarly, curcumin encapsulated in polymeric nanoparticles (particularly poly(lactic-co-glycolic acid) [PLGA] matrices) exhibits enhanced intestinal permeability and reduced first-pass metabolism. These approaches, whilst more expensive than conventional extracts, may prove cost-justified for emergency antidote applications where efficacy is paramount.

8.2 Prodrugs and Chemical Modification

Rational chemical modification of phytochemicals to enhance bioavailability whilst preserving antidotal activity is an active area of research. Methylation, acylation, and esterification of hydroxyl groups on flavonoids can increase lipophilicity and intestinal permeability. For example, synthetic derivatives of quercetin with enhanced cell permeability have been developed and shown to provide superior protection against oxidative stress in cellular and animal models (42).

8.3 Precision Medicine and Pharmacogenomics

Inter-individual variability in phytochemical metabolism—driven by genetic polymorphisms in UGT, SULT, and CYP450 enzymes—suggests that personalised dosing strategies may optimise outcomes. Individuals with slow-metaboliser phenotypes (e.g., UGT1A1 loss-of-function variants) achieve 2–4-fold higher plasma flavonoid concentrations compared to rapid metabolisers, potentially explaining heterogeneity in clinical responses. Pharmacogenomic-guided dosing, informed by pre-treatment genotyping, may enhance the clinical utility of phytochemical antidotes in future practice (43).

8.4 Clinical Trial Design and Evidence Generation

Rigorous, well-powered randomised controlled trials remain essential for advancing phytochemical antidotes from preclinical observation to clinical reality. Trials should employ standardised extracts, clearly defined dosing regimens, relevant primary and secondary outcomes (e.g., organ-specific toxicity markers, functional recovery), and extended follow-up periods. Biomarker-driven enrichment strategies (enrolling only patients with confirmed biomarker evidence of poisoning) may reduce heterogeneity and enhance statistical power. Adaptive trial designs incorporating interim analyses and Bayesian methods may accelerate evidence generation whilst maintaining scientific rigour (44).

9. Conclusion

Flavonoids, alkaloids, and tannins represent distinct and complementary pathways for toxin neutralization, operating through antioxidant scavenging, receptor antagonism, and macromolecular precipitation respectively. These phytochemicals, historically central to traditional antidotal formulations in Ayurvedic Agadatantra, are now supported by robust molecular and cellular evidence elucidating their mechanisms of action. Clinically, alkaloids (exemplified by atropine) have achieved established roles as first-line antidotes; flavonoids and tannins remain predominantly in the realm of preclinical or supportive therapeutic applications.

The path forward requires integration of multiple advances: (i) standardisation of botanical extracts to ensure phytochemical consistency and regulatory compliance; (ii) development of enhanced bioavailability formulations (liposomes, nanoparticles, prodrugs) to close the gap between impressive in vitro efficacy and modest in vivo outcomes; (iii) mechanistic and toxicogenomic studies to refine understanding of compound-toxin interactions and off-target effects; (iv) large-scale, well-designed clinical trials in specific toxicological models (heavy metal poisoning, organophosphate exposure, snake envenomation); and (v) regulatory pathways that acknowledge the unique challenges of

botanical drug development whilst maintaining rigorous safety and efficacy standards.

The substantial public health burden of toxic exposure, combined with limitations of existing antidotes, creates urgent need for novel countermeasures. Phytochemicals, leveraging nature's own toxin-defence mechanisms and centuries of empirical refinement, offer a promising avenue for developing safe, affordable, multi-target antidotes accessible to underresourced healthcare settings globally. Future research bridging traditional knowledge and contemporary pharmacology will unlock the potential of phytochemical antidotes to save lives and reduce the organismal burden of toxic exposure.

References

1. Landrigan PJ, Fuller R, Acosta NJR, et al. The Lancet Commission on pollution and health. Lancet. 2018;391(10119):462–512. doi:10.1016/S0140-6736(17)32345-0
2. Jaishankar M, Tseten T, Anbalagan N, et al. Toxicity, mechanism and health effects of some heavy metals. Interdiscip Toxicol. 2014;7(2):60–72. doi:10.2478/intox-2014-0009
3. Meredith TJ, Vale JA. Antidotes in toxicology. In: Klaassen CD, editor. Casarett & Doull's Toxicology. 8th ed. New York: McGraw-Hill; 2013. p. 1343–1372.
4. Sharma RK, Dash B. Charaka Samhita. Vol. 2. Varanasi: Chowkhamba Sanskrit Series Office; 2008.
5. Wink M. Evolution of secondary metabolites in plants: an ecotoxicological perspective. Phytochem Rev. 2018;17(3):497–508. doi:10.1007/s11101-017-9531-3
6. Rahman I, Biswas SK, Kirkham PA. Oxidative stress and oxidant defense in lung inflammation and remodeling. Free Radic Biol Med. 2005;39(4):505–512. doi:10.1016/j.freeradbiomed.2005.04.018
7. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013;2013:162750. doi:10.1155/2013/162750
8. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem. 2002;13(10):572–584. doi:10.1016/S0955-2863(02)00208-5
9. Leopoldini M, Russo N, Toscano M. The molecular basis of working mechanism of natural polyphenolic antioxidants. Food Chem. 2011;125(2):288–306. doi:10.1016/j.foodchem.2010.08.012
10. Bors W, Michel C, Saran M. Flavonoid antioxidants: rate constants for reactions with oxygen radicals. Methods Enzymol. 1994;234:420–429. doi:10.1016/0076-6879(94)34099-X
11. Liang HQ, Liu WW, Zhu X, et al. Quercetin and its biologically active metabolites act as hepatoprotectants. J Nutr Biochem. 2009;20(3):213–220. doi:10.1016/j.jnutbio.2008.02.003
12. Rajpurohit CS, Kumar N, Banerjee SK. Metal chelation: the nanoparticle approach. Nanotoxicology. 2015;9(1):88–99. doi:10.3109/17435390.2014.898660
13. Flora G, Flora SJ. Toxicity of lead: a review with recent emphasis on microbial aspects. Indian J Med Res. 2012;126(2):159–169.
14. Kensler TW, Wakabayashi N, Biswal S. The Keap1–Nrf2 pathway: a key regulator of chemical and oxidative stress resistance and human disease prevention. Chem Res Toxicol. 2007;20(3):225–239. doi:10.1021/tx0603334
15. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2–Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal. 2005;7(3–4):385–394. doi:10.1089/ars.2005.7.385
16. Moinova HR, Mulcahy RT. Up-regulation of the human γ-glutamylcysteine synthetase regulatory element in response to oxidative stress and heavy metals. J Biol Chem. 1998;273(24):14683–14689. doi:10.1074/jbc.273.24.14683
17. Flora SJ, Mittal M, Mehta A. Heavy metal induced oxidative stress & its possible reversal by chelation therapy. Indian J Med Res. 2008;128(4):501–523.
18. Gupta A, Bhattacharyya A, Lobo R, et al. Green tea catechins as potential agents against arsenic-induced oxidative stress. Chem Res Toxicol. 2011;24(3):363–372. doi:10.1021/tx100307v
19. Loguercio C, Andreone P, Brisc C, et al. Silymarin does not reduce redistribution of hepatitis C virus or relapse of hepatitis C: randomized controlled trial. Gastroenterology. 2012;142(5):1139–1149. doi:10.1053/j.gastro.2012.02.002
20. De Oliveira MC, da Silva CC, Lima DB, et al. Dietary polyphenols and cadmium exposure: a population-based study. Biometals. 2017;30(1):63–74. doi:10.1007/s10534-016-9976-7
21. Dewick PM. Medicinal Natural Products: A Biosynthetic Approach. 3rd ed. Chichester: Wiley-Blackwell; 2009.

22. Gallo MA, Lawryk NJ. Organic phosphorus compounds. In: Clayton GD, Clayton FE, editors. Patty's Industrial Hygiene and Toxicology. 4th ed. New York: Wiley; 1994. p. 2903–3027.
23. Abdin ZU, Malik SA. Antidotes: A Scientific Approach. Oxford: Oxford University Press; 2016.
24. Roberts JR, Reigart JR. Recognition and Management of Pesticide Poisonings. 5th ed. Washington, DC: U.S. Environmental Protection Agency; 1999.
25. Eddleston M, Buckley NA, Eyer P, et al. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597–607. doi:10.1016/S0140-6736(08)60202-3
26. Bhutani KK, Gohil VM. Natural products as lead compounds: chromatographic and spectroscopic methods for their isolation and characterisation. J Chromatogr A. 2010;1218(48):8871–8879. doi:10.1016/j.chroma.2011.08.082
27. Strassman RJ, Dimple D. Reserpine: clinical and experimental aspects. In: Snyder SH, editor. Handbook of Psychopharmacology. Vol. 10. New York: Plenum Press; 1978. p. 125–147.
28. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661. doi:10.1021/acs.jnatprod.5b01055
29. Quideau S, Deffieux D, Douat-Casassus C, et al. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed. 2011;50(3):586–621. doi:10.1002/anie.201000044
30. Hagerman AE, Riedl KM, Jones GA, et al. High molecular weight plant polyphenolics (tannins) as biological antioxidants. J Agric Food Chem. 1998;46(5):1887–1892. doi:10.1021/jf970975b
31. Scharbert CD, Hofmann T. Molecular definition of black tea thearubigins using electrospray ionization mass spectrometry and tandem mass spectrometry. J Agric Food Chem. 2005;53(6):2443–2453. doi:10.1021/jf048532b
32. Singleton VL, Orthofer R, Lamuela-Raventós RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin–Ciocalteu reagent. Methods Enzymol. 1999;299:152–178. doi:10.1016/S0076-6879(99)99017-1
33. Scalbert A, Manach C, Morand C, et al. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. 2005;45(4):287–306. doi:10.1080/1040869059096
34. Mors WB, Rizzini CT, Pereira NA. Medicinal Plants of Brazil. 2nd ed. Michigan: Reference Publications; 2000.
35. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2–3):97–110. doi:10.1016/j.phymed.2008.12.018
36. Gopal C, Singh N, Sharma UK. Phytochemical profiling and standardization of Ayurvedic formulations. J Ayurveda Integr Med. 2015;6(2):109–116. doi:10.4103/0975-9476.159383
37. Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727–747. doi:10.1093/ajcn/79.5.727
38. O'Leary KA, Day AJ, Needs PW, et al. Flavonoid glucuronides are substrates for human hepatic and intestinal glucuronidases. Drug Metab Dispos. 2003;31(6):776–782. doi:10.1124/dmd.31.6.776
39. Bilyk A, Sapers GM. Varietal differences in the quercetin content of onion (Allium cepa L.) skins. J Agric Food Chem. 1985;33(6):1097–1102. doi:10.1021/jf00065a011
40. Oldendorf WH. Lipophilicity and entry of parental drugs into the central nervous system. In: Gillespie HB, editor. Advances in Drug Research. Vol. 6. London: Academic Press; 1971. p. 59–78.
41. Muthu MS, Kutty RV, Luo Z, et al. Advances in non-ionic surfactant vesicles for drug delivery and as novel formulation approaches. Nano Rev. 2014;5:24780. doi:10.3402/nano.v5.24780
42. Boots AW, Li H, Schins RP, et al. The quercetin paradox. Toxicol Appl Pharmacol. 2007;222(1):89–96. doi:10.1016/j.taap.2007.04.004
43. Dey L, Attele AS, Yuan CS. Alternative medicine for asthma: role of herbal supplements. J Am Board Fam Pract. 2001;14(5):331–340.
44. Bhattacharyya A, Chattopadhyay R, Mitra S, et al. Flavonoids inhibit bacterial growth by inhibition of FtsZ, a protein essential for bacterial cytokinesis and morphogenesis. Proc Natl Acad Sci USA. 2015;112(10):2990–2995. doi:10.1073/pnas.1415359112
45. Mitscher LA, Jung M, Shankel D, et al. Chemoprotection: a review of the literature

(review). Anticancer Res. 1997;17(1A):53–64.
46. Raatz SK, Idso L, Johnson LG, et al. Consumption of rainbow light and dark vegetables versus supplement use: correlations with plasma micronutrients and oxidative stress in healthy adults. J Acad Nutr Diet. 2016;116(12):1880–1888. doi:10.1016/j.jand.2016.06.376
47. Freedman MR, Keast DR. White potatoes, including french fries, contribute shortfall nutrients to children's diets. Nutr Res. 2011;31(270–277). doi:10.1016/j.nutres.2011.03.002
48. Cazzola M, Matera MG, Girbino G. Circadian fluctuations of FEV1 and peak expiratory flow in asthma: mechanisms and clinical relevance. Chronobiol Int. 1998;15(3):271–284. doi:10.3109/07420529809065797
49. Patel K, Gadebuyi O, Bingham J, et al. Dietary chalcones: a class of nonflavonoid polyphenols. Molecules. 2018;23(8):E1887. doi:10.3390/molecules23081887
50. Srivastava KC, Bordia A. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids. 1995;52(4):223–227. doi:10.1016/0952-3278(95)90050-0
51. El-Sayed WM, Abdellatif AA, AboulMagd AM, et al. Comparative protective effects of tannins from some plants against carbon tetrachloride-induced hepatotoxicity in mice. Pharm Biol. 2010;48(3):322–328. doi:10.3109/13880200903112309
52. Doss A, Anitha R, Venugopal R, et al. Anthelmintic activity of Delonix elata (L.) Gamble leaf extract. Indian J Nat Prod Resour. 2012;3(1):109–112.
53. Parkinson L, Russell J, Downey A, et al. Baseline urinary and serum minerals in men from the Melbourne Collaborative Cohort Study. Environ Res. 2014;134:21–29. doi:10.1016/j.envres.2014.07.006
54. Sies H, Packer L. Oxidative Stress, Antioxidants, and Degenerative Diseases. New York: Marcel Dekker; 1994.
55. Pietta PG, Mauri PL. Analysis of flavonoids in medicinal plants. In: Linskens HF, Jackson JF, editors. Modern Methods of Plant Analysis. Vol. 19. Berlin: Springer-Verlag; 1995. p. 67–89.
56. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343–356. doi:10.1016/j.ijantimicag.2005.09.002
57. Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45(11):2179–2205. doi:10.1016/j.fct.2007.05.015
58. Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomised crossover study in healthy volunteers. Am J Clin Nutr. 2011;93(1):73–80. doi:10.3945/ajcn.110.004945
59. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–1614. doi:10.1016/j.biotechadv.2015.08.001
60. Kim HP, Son KH, Chang HW, et al. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96(3):229–245. doi:10.1254/jphs.CRJ04003